Loading...
Loading...
Browse all stories on DeepNewz
VisitMedicare Part D to Cover Eli Lilly’s Zepbound for Sleep Apnea Treatment Following FDA Approval, Creating Opportunity for $LLY
Jan 9, 2025, 02:31 PM
The Centers for Medicare & Medicaid Services (CMS) has announced that Medicare will now cover Eli Lilly's Zepbound for the treatment of obstructive sleep apnea (OSA). This decision follows the drug's recent approval by the FDA, making Zepbound the first medication specifically designed for moderate-to-severe OSA. The coverage under Medicare Part D plans presents a substantial opportunity for Eli Lilly, as it could lead to increased diagnoses and treatment of sleep apnea among patients. However, reports indicate that the costs associated with this coverage could be significant for some patients.
View original story
Markets
Yes • 50%
No • 50%
Stock price data from financial markets (e.g., NYSE, NASDAQ)
No • 50%
Yes • 50%
Prescription volume data from healthcare industry reports or CMS data
No • 50%
Yes • 50%
News reports and legal filings related to Zepbound
Less than 500,000 • 25%
More than 2 million • 25%
1 million to 2 million • 25%
500,000 to 1 million • 25%
Prescription data from CMS or healthcare industry reports
CPAP devices • 25%
Other treatments • 25%
Zepbound • 25%
Alternative medications • 25%
Market share data from healthcare industry reports
More than $2 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Financial reports from Eli Lilly or CMS data